enthusiasm dramatically outpaces science FDA Category 2 classifications for peptides like Semax reflect absence of FDA-standard evidence, not documented harmsRussian clinical experience suggests reasonable safety, but long-term effects by Western standards remain uncharacterized Established interventionsexercise, Mediterranean diet, sleep optimization, cardiovascular risk management, cognitive engagementhave far more consistent evidence than any peptide for dementia risk reduction For Research Prioritization Compounds meriting continued investigation: GLP-1 Agonists: Prevention trials in preclinical/presymptomatic populations, testing compounds with better brain penetration (dulaglutide, lixisenatide) SS-31/Elamipretide: Cognitive outcomes in mitochondrial disease populations, potential expansion to brain aging indications P21: Phase I human trials to establish safety, pharmacokinetics, and proof-of-mechanism for CNTF-pathway neurogenesis Klotho: Watch for Phase 1 results from Jocasta Neuroscience (expected 2027-2028)

Alcohol Consumption: Your liver prioritises alcohol detoxification over all other functions, which depletes glutathione stores within hours of consumption
Longitudinal changes in brain metabolites following pediatric concussion
Convenient in-home or hotel treatments
Alpha BRAIN claims to support memory, mental speed, and focus
The science behind the GHK-Cu peptide with woman and aging shows us that replenishing this vital compound can help reset our cells to a more youthful state